SecBot SecBot
SECBOTREPLAY Home › Report › JNJ

JNJ · Johnson & Johnson announced the retirement of Jennifer Taubert, EVP and…

JOHNSON & JOHNSON · 8-K filed Aug 4, 2026 at 08:48 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Aug 4, 2026 at 08:48 ET

Johnson & Johnson announced the retirement of Jennifer Taubert, EVP and Worldwide Chairman of Innovative Medicine, effective September 1, 2026, with Tom Cavanaugh appointed as her successor. This is a routine leadership transition at a mega-cap pharmaceutical company with a named internal replacement, carrying no material financial impact.

  • Jennifer Taubert to retire as EVP, Worldwide Chairman, Innovative Medicine effective September 1, 2026.
  • Tom Cavanaugh appointed as successor, effective September 1, 2026, and will join the Executive Committee.
  • Taubert had a 21-year tenure at J&J; under her leadership, Innovative Medicine grew to more than $60 billion in annual revenue.
  • Cavanaugh has nearly 30 years of biopharma experience, including 9 years at J&J and prior roles at Celgene.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access